Literature DB >> 12951153

Design and synthesis of orally active benzamide derivatives as potent serotonin 4 receptor agonist.

Shuji Sonda1, Toshio Kawahara, Takahiro Murozono, Noriko Sato, Kiyoshi Asano, Keiichiro Haga.   

Abstract

A series of 4-amino-5-chloro-2-methoxy-N-(piperidin-4-ylmethyl)benzamide derivatives bearing an aralkylamino, alkylamino, benzoyl or phenylsulfonyl group at its side chain part at the 1-position on the piperidine ring was synthesized. They were evaluated for serotonin 4 (5-HT(4)) receptor agonist activity by testing their ability to contract the isolated guinea-pig ascending colon. 4-Amino-5-chloro-2-methoxy-N-[1-[5-(1-methylindol-3-ylcarbonylamino)pentyl]piperidin-4-ylmethyl]benzamide (1a, Y-34959) and its related compounds possessed favorable pharmacological profiles for gastrointestinal motility. Unfortunately, the compound 1a showed low bioavailability when given orally presumably due to its poor intestinal absorption rate. Replacement of the 1-methylindol-3-yl carbonylamino moiety of 1a with an aralkylamino (or alkylamino) group did not improve the intestinal absorption rate. Replacement of the 1-methylindol-3-ylcarbonylamino moiety with a benzoyl or phenylsulfonyl group increased the intestinal absorption rate compared with 1a. These compounds revealed good pharmacological profiles for gastrointestinal motility and were superior to 1a in oral bioavailability.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951153     DOI: 10.1016/s0968-0896(03)00412-7

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.

Authors:  Paul D Jones; Hsing-Ju Tsai; Zung N Do; Christophe Morisseau; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2006-07-25       Impact factor: 2.823

2.  1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Authors:  Tristan E Rose; Christophe Morisseau; Jun-Yan Liu; Bora Inceoglu; Paul D Jones; James R Sanborn; Bruce D Hammock
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

3.  ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.

Authors:  Tian Chen; Radhia Benmohamed; Jinho Kim; Karen Smith; Daniel Amante; Richard I Morimoto; Donald R Kirsch; Robert J Ferrante; Richard B Silverman
Journal:  J Med Chem       Date:  2011-12-22       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.